Activation of Protein Kinase C βII by the Stereo-specific Phosphatidylserine Receptor Is Required for Phagocytosis of Apoptotic Thymocytes by Resident Murine Tissue Macrophages*

Jill C. Todt‡, Bin Hu‡, Antonello Punturieri‡‡, Joanne Sonstein‡, Timothy Polak‡, and Jeffrey L. Curtis‡§**

From the ‡Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, the †Comprehensive Cancer Center, and the §Graduate Program in Immunology, University of Michigan Health Care System and the ¶Pulmonary and Critical Care Medicine Section, Medical Service, Department of Veterans Affairs Care System, Ann Arbor, Michigan 48105-2303

We showed previously that protein kinase C (PKC) is required for phagocytosis of apoptotic leukocytes by murine alveolar (AMø) and peritoneal macrophages (PMø) and that such phagocytosis is markedly lower in AMø compared with PMø. In this study, we examined the roles of individual PKC isoforms in phagocytosis of apoptotic thymocytes by these two Mø populations. By immunoblotting, AMø expressed equivalent PKC η but lower amounts of other isoforms (α, βI, βII, δ, ε, μ, and ζ), with the greatest difference in βII expression. A requirement for PKC βII for phagocytosis was demonstrated collectively by phorbol 12-myristate 13-acetate-induced depletion of PKC βII by dose-response to PKC inhibitor Ro-32-0432, and by use of PKC βII myristoylated peptide as a blocker. Exposure of PMø to phosphatidylinerine (PS) liposomes specifically induced translocation of PKC βII and other isoforms to membranes and cytoskeleton. Both AMø and PMø expressed functional PS receptor, blockade of which inhibited PKC βII translocation. Our results indicate that murine tissue Mø require PKC βII for phagocytosis of apoptotic cells, which differs from the PKC isoform requirement previously described in Mø phagocytosis of other particles, and imply that a crucial action of the PS receptor in this process is PKC βII activation.

Phagocytosis, the uptake of large particles (>0.5 μm) via actin-dependent mechanisms (1), is the obligatory means of clearing apoptotic cells during development and in resolving inflammation (2). Only macrophages can efficiently clear the large numbers of apoptotic leukocytes produced during waning immune responses (3–6). Indeed, the efficiency of this process is evidenced by the fact that apoptotic cells are rarely observed in vivo (7); one exception is in the lungs of mice, where apoptotic lymphocytes are easily demonstrable both in health and inflammation (8). This defect in clearance is consistent with the finding that the principal resident lung phagocytes, alveolar macrophages (AMø), exhibit markedly lower capacity for phagocytosis of apoptotic leukocytes, either compared with inflammatory lung Mø (in rabbits) (9) or with resident peritoneal Mø (PMø) (in mice) (10). In the latter system, no disparity between AMø and PMø was detected using three other particle types (10, 11). Murine AMø also exhibited a relative deficit in phagocytosis of apoptotic cells in vitro (10). We have recently found that human AMø also show much lower phagocytosis of apoptotic cells than of other particles in vitro.2 Contrasting the properties of these two types of resident tissue Mø could aid in defining the molecular basis of apoptotic cell recognition, which is poorly understood.

Recognition of apoptotic cells is initiated through at least two pathways. Using a 70-kDa glycosylated type II transmembrane protein called PS-R (12), Mø and other cell types recognize externalized phosphatidylinerine (PS), which translocates from the inner to the outer leaflet of the cell membrane early in apoptosis (13–17). Recognition of externalized PS has been suggested to be both necessary and sufficient to generate a signal for ingestion (13, 18). More recently, the Mø-specific receptor tyrosine kinase Mer has been identified as critical for the phagocytosis of apoptotic cells by murine Mø (19). How signaling from these two receptors leads to apoptotic cell phagocytosis is undefined. A host of other Mø cell surface receptors (reviewed in Ref. 20) have also been implicated in clearance of apoptotic cells, but they appear to be involved principally in adhesion rather than in recognition of cell death (21). Moreover, although we (10) and others (22) have identified a number of differences in expression of adhesion molecules between murine AMø and PMø, blocking experiments using monoclonal antibodies (mAbs) or the arginine-glycine-aspartic acid-serine (RGDS) tetrapeptide have not supported any identified adhesion receptor, including several integrins, as being responsible for the functional difference in phagocytosis (10).

An alternative explanation for disparity between Mø types in apoptotic cell phagocytosis would be differences in postreceptor signal transduction. A logical candidate for such a difference is...
protein kinase C (PKC), because we and others have shown that it is required for apoptotic cell clearance (11, 23). PKC comprises a family of related serine/threonine kinases divided into three groups on the basis of structure and cofactor requirements (24). Activation of PKC requires phosphorylation on serines/threonines, displacement of its autoinhibitory pseudosubstrate domain, and translocation to specific cytoskeletal and intracellular membrane sites of action (25). Activation of the conventional group (cPKC) (α, β, γ, and δ) is calcium and diacylglycerol (DAG)-dependent. Activation of the novel group (nPKC) (ε, η, and θ) also depends on binding of DAG, but it is calcium-independent. The atypical group (αPKC) (ζ and η) cannot be activated by calcium or DAG. All PKC family members bind PS on the cytosolic leaflet of the cell membrane, but αPKCs require additional incompletely defined lipid activators (24). Another isoform, PKC μ (often called PKD in the mouse), does not fit into any of the major groups. PKC μ contains two unique hydrophobic domains in its amino terminus and is phospholipid-dependent but calcium-insensitive (26). Individual cell types usually express several PKC isoforms, each of which appears to mediate unique functions (27). Even the 50-amino acid difference in the alternatively spliced forms of PKC β (βI and βII) appears to be responsible for the unique role of each PKC β isoform (28, 29). Thus, differences between murine AMs and PMs in PKC isoform expression or function could explain the functional difference between these two cell types in apoptotic cell phagocytosis.

We recently showed (11) that phagocytosis of apoptotic thymocytes by murine AMs and PMs was reduced by the non-specific PKC inhibitor staurosporine and by Gö 6976 but only incompletely by calphostin C. Gö 6976 has been reported to act as a partially selective inhibitor of the cPKC α and β isoforms (30), whereas calphostin C has greater activity against nPKCs than cPKCs (31). However, current data on the specificity of these inhibitors are too inconclusive (32) to allow us to predict with certainty which isoforms are involved. Therefore, in this study, we used six approaches to further define the PKC isoform(s) involved in Mø phagocytosis of apoptotic thymocytes. First, because the pattern of PKC isoforms in primary murine tissue Møs has not been described, we analyzed PKC isoform expression using isotype-specific antibodies and Western blotting. Second, we tested the effect of overnight exposure of Møs to phorbol 12-myristate 13-acetate (PMA), which depletes cPKC and nPKC isoforms by interacting with their DAG-binding sites, on AMs and PMs phagocytosis of apoptotic thymocytes. Third, we employed the isoform-selective inhibitors, rottlerin and Ro-32-0432. Fourth, we tested the effect of myristoylated PKC βI and Ro-32-0432. Fourth, we tested the effect of myristoylated PKC βI and Ro-32-0432. Fourth, we tested the effect of myristoylated PKC βI and Ro-32-0432. Fourth, we tested the effect of myristoylated PKC βI and Ro-32-0432. Fourth, we tested the effect of myristoylated PKC βI and Ro-32-0432. Fourth, we tested the effect of myristoylated PKC βI and Ro-32-0432. Finally, we examined the effect of PS liposomes, as models for apoptotic thymocytes, show that an antibody against PS-R blocks translocation of PKC βI in response to PS liposomes, and suggest that relative deficiency of PKC βI and possibly other PKC isoforms may partially explain the functional difference in apoptotic cell clearance by AMs.

**Experimental Procedures**

**Reagents**—Rottlerin and Ro-32-0432 were purchased from Calbiochem. PMA, PBS, RPMI 1640, fetal bovine serum, HEPES, pyruvate, 1 kb Plus brand up markers and penicillin/streptomycin were obtained from Invitrogen. Dimethyl sulfoxide, dexamethasone, 2-mercaptoethanol, sodium deoxycholate, glycerol, NaCl, Tris-HCl, Triton X-100, Tween 20, 1 kb Plus brand up markers, t-α-phosphatidylinositol (PI), t-α-PS, and phosphatase inhibitor mixture II were purchased from Sigma. Antibodies and blocking peptides for PKC isoforms and horseradish peroxidase-conjugated anti-rabbit IgG were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Complete mini-protease inhibitor tablets and phosphatase inhibitor tablets were obtained from Roche Molecular Biochemicals (192 μm polyvinylidene difluoride membrane, nonfat dry milk blocker, and 10% Ready Alumide gels were obtained from Bio-Rad. SuperSignal West Femto Maximum Sensitivity substrate was obtained from Pierce. Eastman Kodak Co. X-OMat AR film and eight-well Lab-Tek slides were obtained from Fisher, and horseradish peroxidase-conjugated goat anti-rabbit IgG was generously provided by Dr. Valerie Fadok (National Jewish Medical Center, Denver, CO) as a culture supernatant; in selected experiments, a commercial preparation of this mAb (Cascade BioScience, Winchester, MA) at 90% purity, as confirmed by high pressure liquid chromatography and mass spectroscopy performed by the manufacturer.

*Mice*—All experiments were performed using pathogen-free C57BL/6 female mice purchased from Charles River Laboratories Inc. (Wilmington, MA) at 7–8 weeks of age and used at 8–14 weeks of age. Mice were housed in the Animal Care Facility at the Ann Arbor VA Medical Center, which is fully accredited by the American Association for Accreditation of Laboratory Animal Care. This study was approved by the Animal Care and Use Committee of the local institutional review board.

*Isolation and Culture of Møs*—Møs were euthanized by asphyxia in a high CO2 environment, which we have previously shown does not impair the capacity of AMs to ingest apoptotic thymocytes (10). Resident AMs and PMs were harvested and cultured as previously described (10). Møs were isolated by adherence onto tissue culture plates (for protein isolation) or eight-well Lab-Tek slides (for phagocytosis assay) for 2–4 h at 37 °C in 5% CO2 in complete medium (RPMI 1640 containing 10% heat-inactivated fetal bovine serum, 25 mM HEPES, 2 mM l-glutamine, 1 mM pyruvate, 100 units/ml penicillin/streptomycin, 55 μg/ml 2-mercaptoethanol). Nonadherent cells were removed by gentle washing. In experiments in which PKC localization was analyzed by Western blotting, complete medium was replaced with serum-free medium for 1 h.

*Preparation of Apoptotic Thymocytes*—Thymuses were harvested from normal mice and minced to yield a single cell suspension. To induce apoptosis, thymocytes were resuspended in complete medium containing a concentration of 1 × 107 cells/ml and incubated for 6 h in complete medium containing 1 μM dexamethasone. This treatment yields a population with a low percentage (mean 13.4%) of late apoptotic or necrotic cells (10, 11).

*Western Analysis of PKC Isozymes*—Resident AMs and PMs from normal mice were isolated and plated at 1.0 × 106 cells/ml on 100 × 22-mm plates in medium containing 10% serum and incubated for 2 h at 37 °C and 5% CO2. Next, Møs were washed and solubilized in ice-cold lysis buffer consisting of 1.0% Triton X-100, 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, and 10% glycerol with protease inhibitors (complete mini-tab) and phosphatase inhibitor mixture II (1:100) for 30 min on ice. After sonication for 5 s and centrifugation at 13,000 × g for 3 min, 7 μg of protein/sample was run on a 10% acrylamide gel under reducing conditions and transferred to a polyvinylidene difluoride membrane using 25 mM Tris, 192 mM glycine, and 10% Ready Alumide gels were obtained from Bio-Rad. SuperSignal West Femto Maximum Sensitivity substrate was obtained from Pierce. Eastman Kodak Co. X-Omat AR film and eight-well Lab-Tek slides were obtained from Fisher. mAb 217 (anti-murine PS-R; rat IgM) was generously provided by Dr. Valerie Fadok (National Jewish Medical Center, Denver, CO) as a culture supernatant; in selected experiments, a commercial preparation of this mAb (Cascade BioScience, Winchester, MA) at 90% purity, as confirmed by high pressure liquid chromatography and mass spectroscopy performed by the manufacturer.

The medium was then removed and replaced with serum-free medium containing 10% serum and incubated for 2 h at 37 °C and 5% CO2. Next, Møs were washed and solubilized in ice-cold lysis buffer consisting of 1.0% Triton X-100, 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, and 10% glycerol with protease inhibitors (complete mini-tab) and phosphatase inhibitor mixture II (1:100) for 30 min on ice. After sonication for 5 s and centrifugation at 13,000 × g for 3 min, 7 μg of protein/sample was run on a 10% acrylamide gel under reducing conditions and transferred to a polyvinylidene difluoride membrane using 25 mM Tris, 192 mM glycine, 20% methanol. Blots were blocked with 5% nonfat dry milk in PBS (blocker), incubated with the appropriate anti-PKC isoform antibody (1:1000 dilution in blocker), and washed five times for 5 min each with PBS containing 0.1% Tween 20. Blots were incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG (diluted 1:10,000 in PBS containing 5% nonfat dry milk), and the chemiluminescence signal was developed by adding a peroxidase/luminol-based substrate (Supersignal Femto reagent; Pierce). The identity of PKC isoforms on Western blots was verified using isoform-specific blocking peptides. No bands were seen when blots were stained using horseradish peroxidase-conjugated goat anti-rabbit IgG alone.

To analyze the subcellular distribution of PKC isoforms, Møs were isolated and plated at 1.0 × 106 cells/ml on 30 × 15-mm plates in medium containing 10% serum and incubated for 2 h at 37 °C and 5% CO2. The medium was then removed and replaced with serum-free medium for 1 h followed by washing and scraping in cold PBS. Next, Møs were sonicated for 10 s in 50 mM Tris, pH 8.0, 9 mM EDTA and then centrifuged at 100,000 × g for 45 min. The supernatant was collected.
and defined as the cytosolic fraction. The pellet, defined as the membrane and cytoskeleton fractions, was solubilized in ice-cold lysis buffer (defined above) for 30 min on ice. This solubilized pellet fraction was sonicated for 3 s and then centrifuged at 13,800 × g for 3 min. Equal amounts of protein were run on a 10% SDS-PAGE gel under reducing conditions, transferred to the polyvinylidene difluoride membrane, and stained as described above.

**Preparation of Liposomes**—To produce liposomes, PS or the negatively charged control lipid PI was dried under N₂ and resuspended in serum-free medium by vortexing. Liposome size was determined by Coulter counter analysis to be in a similar range as apoptotic thymocytes, 2–3.2 μm. In these experiments, Møs were incubated for 1 h in serum-free medium, liposomes in serum-free medium were added to Mø monolayers in a final PS or PI concentration of 0.11 μM, and Mø and liposomes were co-incubated for the indicated time at 37 °C and 5% CO₂. Cells were washed and scraped in cold PBS; sonicated for 10 s in 50 mM Tris, pH 8.0, 9 mM EDTA; and centrifuged at 100,000 × g for 45 min.

**RNA Preparation and Reverse Transcriptase-PCR**—Total RNA was isolated from adherent AMs and PMs using TRIzol (Invitrogen). Reverse transcription was performed using kits from Invitrogen. The primer sets used were the following: for mouse PS-R (GenBank™ accession number AF304118), forward CTC ACG ATG AAC CAC AAG AGC and reverse GGA CCA GCC CTC TTG TGC ATT; for mouse glyceralddehyde-3-phosphate dehydrogenase (GenBank™ accession number M32599), forward GGT CCG TGT GAA CCG ATT TGG and reverse ATG AGG TTC ACC ACC CTG TTG. The expected PCR product size was 685 bp for PS-R and 965 bp for glyceralddehyde-3-phosphate dehydrogenase. PCR products were analyzed on a 2% agarose gel and stained with ethidium bromide. The identity of the target products was confirmed by sequencing.

**Flow Cytometric Analysis**—Apoptosis was measured by simultaneous annexin V and propidium iodide staining (apoptosis detection kit; R & D Systems, Minneapolis, MN) according to the manufacturer’s protocol. Cells were analyzed without fixation by flow cytometry within 1 h of staining. Staining of surface receptors and flow cytometry were performed as previously described in detail (33) using a FACScan cytometer (BD PharMingen) running Cell Quest software on a PowerPC microcomputer (Apple, Cupertino, CA) for data collection and analysis. A minimum of 10,000 cells were analyzed.

**Phagocytosis Assay**—Phagocytosis of apoptotic thymocytes in vitro was assayed by co-incubations of 0.5–2.0 × 10⁶ apoptotic Møs with 2.0 × 10⁶ apoptotic thymocytes for 90 min at 37 °C in 5% CO₂. Adherence of apoptotic thymocytes to Møs was defined above and as the adhesion index, which was generated by multiplying the percentage of adherence-positive Møs by the mean number of adherent thymocytes per Mø. The phagocytic index, which was generated by multiplying the percent-ing at least one ingested thymocyte (percentage of phagocytosis) and as the percentage of phagocytic cells, was defined as the number of cells ingested per Mø.

**Results**

**AMs Express Lower Amounts of Most PKC Isoforms than Do PMs**—Western blot analysis using PKC isoform-specific antibodies demonstrated markedly lower expression of PKC α, βI, βII, δ, ε, μ, and ξ in resident murine AMs compared with resident murine PMs (Fig. 1). By contrast, AMs had slightly higher expression of PKC η. Staining did not detect expression of PKC γ or PKC λ in either murine AMs or PMs, in agreement with previous analyses of human tissue Mts (24, 37), and we did not test expression of the lymphocyte-specific isoform PKC θ.

**Effect of Overnight PMA Treatment on Mφ Phagocytosis of Apoptotic Thymocytes**—Chronic (18-h) PMA treatment depletes cPKCs and nPKCs but not aPKCs, with the degree to which individual isoforms are affected depending on the cell type and the PMA concentration (27, 37–39). In preliminary experiments, the concentration and time of PMA addition were optimized to achieve maximal inhibition of apoptotic cell phagocytosis. We determined that the conditions used were nontoxic, as indicated by assay of lactate dehydrogenase release. Western blot analysis on AMs and PMs after overnight treatment using 8.1 μM PMA confirmed that PKC α, βI, βII, and δ were significantly depleted (p < 0.05, unpaired t test) by PMA treatment in either of the two types of Mφ (Fig. 2). As anticipated, PKC ε, η, μ, and ξ were not depleted by overnight PMA.
adhesion index, 1.2

indicate that the nPKC isoforms treated; 

experiments is complicated by the uncertainty about the

required. However, rottlerin can inhibit casein kinase II and

PM

—

cPKCs

should be inhibited (41)) but did inhibit phagocytosis at 40 M (a concentration at which cPKCs should

be inhibited (40)) (Fig. 4). Ro-32-0432 had no effect on phagocytosis of apoptotic cells but leave open the question of which cPKC or other

nPKCs and PKC \( \mu \)PKD are not essential for M\( \phi \) phagocytosis of apoptotic thymocytes but leave open the question of which cPKC or other

nPKCs are required.

Rottlerin and Ro-32-0432 Decrease Phagocytosis of Apoptotic Thymocytes at Concentrations at Which They Inhibit cPKCs—To further define which PKC isoforms are essential for phagocytosis, we used two cell-permeable PKC inhibitors, rottlerin and Ro-32-0432, which show a degree of isoform specificity. Rottlerin specifically inhibits PKC \( \delta \) at relatively low concentration (IC\( _{50} \) = 3–6 \( \mu \)M) and other PKC isoforms only at higher concentrations (IC\( _{50} \) for PKC \( \alpha \) and \( \beta \) = 30–42 \( \mu \)M; IC\( _{50} \) for PKC \( \epsilon \), \( \eta \), and \( \zeta \) is 80–100 \( \mu \)M) (40). We found that rottlerin did not inhibit AMs or PMs phagocytosis of apoptotic thymocytes at 10 \( \mu \)M (a concentration at which PKC \( \delta \) should be inhibited (40)), whereas there was significantly decreased phagocytosis at 40 \( \mu \)M (a concentration at which cPKCs should be inhibited (40)) (Fig. 4). Ro-32-0432 had no effect on phagocytosis of apoptotic thymocytes at 9 \( \mu \)M (a concentration at which PKC \( \alpha \) should be inhibited (41)) but did inhibit phagocytosis of apoptotic thymocyte at 28 \( \mu \)M (a concentration at which PKC \( \beta \) but not PKC \( \epsilon \) should be inhibited (41)) (Fig. 5). These data argue against a requirement for PKC \( \delta \) or PKC \( \epsilon \) for phagocytosis of apoptotic cells and provide additional support for the possibility that a cPKC, especially PKC \( \beta I \) or \( \beta II \), is required. However, rottlerin can inhibit casein kinase II and cAMP-dependent protein kinase with IC\( _{50} \) values of 30 and 78 \( \mu \)M, respectively, and can also inhibit calmodulin kinase III with IC\( _{50} \) of 5.3 \( \mu \)M (32). Moreover, interpretation of these experiments is complicated by the uncertainty about the

degree to which the reported IC\( _{50} \) values for these inhibitors can be extrapolated from the \textit{in vitro} assays with which they were developed to intact cells. Therefore, we looked for an

PKC βII in Phagocytosis of Apoptotic Cells

Fig. 5. Ro-32-0432 inhibits Mø phagocytosis of apoptotic thymocytes in a dose-dependent fashion. Phagocytosis of apoptotic thymocytes by resident AMs and PMs was determined after 30 min of incubation under the following conditions: control medium (gray bars), 9 µM Ro-32-0432 (black bars), 28 µM Ro-32-043 (white bars). A, percentage of phagocytic Mø; B, phagocytic index. Data are mean ± S.E. of four replicates in two experiments. *p < 0.05, analysis of variance with post hoc Dunnett’s testing.

Additional method to verify a requirement of PKC β during phagocytosis.

Myristoylated PKC βII Blocking Peptide Inhibits Phagocytosis of Apoptotic Thymocytes by AMs and PMs—Because all data thus far implicated a cPKC as a necessary signaling component during phagocytosis of apoptotic thymocytes, we tested the effect of cell-permeable myristoylated peptides derived from the carboxyl terminus of the V5 region of PKC α, βI, or βII, on phagocytosis of apoptotic thymocytes. Peptides from this region were selected based on the following rationale. First, this region (specifically the last 13 amino acids) has been suggested to contribute to phosphatidylglycerol-induced activation of PKC βII (29) and, via interaction with the C2 region, to calcium-and PS-mediated activation of PKC βII (42). Second, the V5 region of PKC α, specifically the QSAV sequence, has been shown to interact with PICK1, a PKC-binding protein that appears to target PKC α to appropriate intracellular sites for transduction of isozyme-specific signals (43). Third, the PKC βII peptide used in this study has previously been shown to inhibit the binding of a maltose-binding protein-PKC βII fusion protein to RACK1 (34), confirming its functional activity. Fourth, the V5 region is the only site at which PKC βI and PKC βII amino acid sequences differ. Finally, these βI and βII peptides comprise part of the antigenic sequences used for development of the isozyme-specific antibodies used in this study.

We found that the myristoylated PKC βII peptide significantly decreased phagocytosis of apoptotic thymocytes by both AMs and PMs, whereas the myristoylated PKC α and PKC βI peptides had no effect (Fig. 6). These results provide direct evidence that PKC βII is required for Mø phagocytosis of apoptotic thymocytes.

PS Liposomes Stimulate Translocation of PKC Isoforms βI, βIII, δ, ε, μ, and ζ to Membrane and Cytoskeleton Fractions—Translocation from cytosol to membrane or cytoskeleton fractions upon activation is a major mechanism of PKC regulation (26, 44), leading us to investigate translocation of individual PKC isoforms during the phagocytic process. However, preliminary experiments showed that the abundant expression of multiple PKC isoforms in viable murine thymocytes was retained upon induction of apoptosis, making use of apoptotic thymocytes for these studies unfeasible. Instead, we substituted PS liposomes, which have been used previously as models for apoptotic cells (45, 46). Liposome clearance by AMs and PMs has been shown to require phagocytosis and not to result from membrane fusion (47, 48), further supporting use of PS liposomes for these studies. Based on the practical consideration that our previous experiment showed that AMs express much lower amounts of multiple PKC isoforms (Fig. 1), we performed these experiments using only PMs. Time points were selected based on our previous study of the kinetics of phagocytosis (10).

We found that PS liposomes strongly stimulated translocation of PKC βI, βII, δ, ε, μ, and ζ from the cytosol to the membrane and cytoskeleton fraction of PMs by 10 min, whereas control PI liposomes had no effect (Fig. 7). PS liposomes specifically stimulated slight translocation of PKC α, and PI liposomes also slightly stimulated translocation of PKC δ and ε, whereas neither type of liposome had a significant effect on the localization of PKC η. Thus, several members of all three groups of PKC isoforms are specifically translocated in response to PS exposure.

Resident Murine Mø Express the Stereo-specific PS-R’, Which Mediates PKC Translocation in Response to PS Liposomes—These data raised the question of whether the stereo-specific PS-R’ identified by Fadok and associates (12) could contribute to PKC activation during Mø recognition of apoptotic cells. Expression of PS-R’ was detected by multiple methods in both types of Mø. Reverse transcriptase-PCR demonstrated equivalent PS-R’ mRNA in AMs and PMs (Fig. 8A). Flow cytometry showed distinct surface expression of PS-R’ by both types of Mø (Fig. 8, B and C). Although specific staining and background staining of both Mø types varied slightly between experiments,
mean channel fluorescence of PMø was generally somewhat higher than that of AMø (e.g., in the experiment shown in Fig. 8), mean channel fluorescence was 484.7 for PMø versus 161.4 for AMø). Hence, the absence of PS-R’ expression by AMø did not appear to explain our previous finding of decreased phagocytosis of apoptotic cells (10).

To determine whether PS-R’ was functional on both types of Mø, we performed phagocytosis and adhesion assays in the presence of the blocking mAb 217. Blockade of PS-R’ specifically and profoundly inhibited phagocytosis of apoptotic thymocytes (Fig. 9, A and B), in agreement with previous data using this mAb on other cell types (12). However, the same concentration of mAb 217 had no effect on adhesion of apoptotic thymocytes to either type of Mø (Fig. 9, C and D). These data confirm that both AMø and PMø express functional PS-R’, but that this receptor does not mediate apoptotic cell adhesion.

To determine whether stimulation via PS-R’ induced PKC activation, we tested whether mAb 217 could inhibit PS liposome-induced translocation of PKC βII to particulate fractions. In the presence of control IgM, PS liposomes induced translocation of PKC βII from cytosolic fractions to membrane and cytoskeletal fractions (Fig. 10, top row), as anticipated from our previous results (Fig. 7). Such induced translocation was inhibited when PS-R’ was blocked using mAb 217 (Fig. 10, bottom row). These results indicate that the induction of PKC βII translocation by PS liposomes and, by implication, by apoptotic cells is mediated through PS-R’. Because mAb 217 itself has been shown to have agonist activity as indicated by its ability to stimulate transforming growth factor-β expression (12), in separate experiments, we tested whether this mAb in the absence of PS liposomes could induce PKC translocation. No induction of PKC translocation was observed for PKC βII or any of the other seven isoforms tested. Thus, the effects shown in Fig. 10 result from inhibition of PS-induced translocation mediated via PS-R’ and not from agonist activity of mAb 217 itself.

**DISCUSSION**

The principal findings of this study indicate that PKC βII is required for phagocytosis of apoptotic cells by murine tissue Mø and that the activation of this PKC isozyme in response to PS liposomes is mediated by PS-R’. These conclusions are based on a consistent body of evidence, including the effects on phagocytosis of PKC depletion by overnight PMA treatment, dose-specific inhibition using rotterlin and Ro-32-0432, and a specific myristoylated blocking peptide corresponding to the carboxyl terminus of PKC βII as well as by inhibition of PS-induced translocation of PKC βII when PS-R’ was blocked. Because adhesion of apoptotic thymocytes to Mø was not decreased by the PKC inhibitor staurosporine (11) or by overnight PMA treatment, the inhibition of phagocytosis seen in this study appears to result from recognition events following binding. Our results also showed that exposure to PS liposomes induced translocation of several other PKC isoforms (βI, δ, ε, μ, and ζ) to a lesser degree α) to membrane and cytoskeletal fractions. However, based on results of the inhibitor and PMA studies, translocation of these latter isoforms appears to be unnecessary for phagocytosis. Furthermore, our results indicated that the stereo-specific PS-R’ did not mediate adhesion of apoptotic cells, consistent with its predicted short extracellular domain. Finally, Western blot analysis showed that murine AMø have markedly lower expression of PKC βII and of multiple other PKC isoforms (α, βII, δ, ε, μ, and ζ), providing a partial explanation for the previously demonstrated relative deficit in apoptotic cell phagocytosis by that cell type (10). These novel findings advance the understanding of signal transduction during Mø recognition and ingestion of apoptotic cells.
Larsen et al. (50) found that PKC δ and ε were necessary for FcγR-mediated phagocytosis itself. PKC βII and its anchoring protein RACK1 have been found to be up-regulated in rat AMs upon maturation of functional responses such as tumor necrosis factor-α or hydrogen peroxide production and lysozyme release (57). Significantly, however, none of these previous studies have confirmed a role for PKC βII in phagocytosis of other particles.

PKC β and βII are products of alternative mRNA splicing of a single gene; they are identical for the first 621 amino acids and differ only in their carboxyl-terminal 50–52 amino acids. The myristoylated blocking peptides we used correspond to this area of difference and therefore were specific. The absence of effect of myristoylated β peptide on phagocytosis agrees with previous reports that these isoforms have unique functions (28). Early studies found that although both isoforms translocate to membranes in response to short-term PMA exposure, only PKC βII is an actin-binding protein that translocates to the actin-based cytoskeleton (58). However, recent studies have reached conflicting conclusions, showing either that PKC βII does not co-distribute with actin-based cytoskeleton upon PMA treatment (59) or that PKC β as well as other PKC isoforms bind to and are activated by F-actin (60, 61).

That phagocytosis of apoptotic targets might involve unique signal transduction elements should not be surprising. In contrast to the proinflammatory responses activated by phagocytosis via other pathways (1), phagocytosis of apoptotic cells is continuous during development and antiphlogistic during resolving inflammation (62–65). The finding that murine thioglycollate-elicited PMs secreted MIP-2/CXCL2 upon ingestion of apoptotic T cells has been interpreted as a contradiction to this principle (66), but an alternative view would be that production of this chemokine in the absence of other proinflammatory signals simply recruits Møs as part of the beneficial clean-up process. Ingestion of apoptotic T cells has been found to compromise Mø host defense functions in vivo (67). Hence, we speculate that the relatively deficient phagocytosis of apoptotic leukocytes by AMs may be a beneficial evolutionary adaptation. Even moderate suppression of chemokine and monokine secretion in the lungs may tip the balance in favor of virulent pathogens such as enteric Gram-negative bacteria and Staphylococcus aureus or may be sufficient to permit evasion of innate immunity by less virulent pathogens such as anaerobes.

Our current data showing that both murine AMs and PMs respond to PMA agrees with the preponderance of results in other systems. Heale and Speert (68) found that PMA can reverse the inability of murine AMs to ingest Pseudomonas aeruginosa. Although Peters-Golden et al. (69) initially reported that PMA caused release of arachidonic acid in a PKC-dependent manner in rat PMs but not AMs, a more recent paper from that group showed that the augmentation of FcγR-mediated phagocytosis in rat AMs by leukotrienes is PKC-dependent, indicating that AMs can respond to PKC-stimulatory molecules (70).

Our analyses of PS-R′ advance the understanding of this receptor’s role in the process of apoptotic cell clearance. The gene for this receptor has been conserved with exceedingly high fidelity across greater than 600 million years of evolution between organisms as disparate as Caenorhabditis elegans, Dro sophila melanogaster, and mammals (12). This conservation and the fact that it was not previously identified by genetic analysis of C. elegans mutants (which suggests that its deletion may be lethal) speaks to its fundamental importance. Because we show that mAb 217 does not block adhesion, the PS-R′ function must depend on initial adhesion via other receptors. Thus, it is a recognition molecule that imparts specificity to the

The finding that PKC βII is necessary for Mø phagocytosis of apoptotic cells is important because it differs from previously defined requisites for Mø phagocytosis of other types of particles. Allen and Aderem (49) found that during ingestion of zymosan by lipopolysaccharide-stimulated PMs, PKC α and myristoylated, alanine-rich protein kinase C substrate co-localize with F-actin and talin adjacent to nascent phagocytic cups. During FcγR-mediated phagocytosis, PKC α (50), β (51), γ (52), δ (53), and ε (54) have all been shown to localize to the phagosome membrane, with the specific PKC isoform recruited dependent on the state of Mø differentiation and the exact FcγR involved (52). However, because PKC co-localization may be a consequence rather than a necessary process, other groups have investigated blockade of PKC function. Overexpression of a dominant negative mutant of PKC α in the murine Mø cell line RAW 264.7 reduced phagocytosis of IgG-opsonized sheep red blood cells (54) but not phagocytosis of Leishmania donovani promastigotes (55). Although the former finding was interpreted to indicate a requirement for PKC α in FcγR-mediated phagocytosis, such observations must be interpreted with caution, because overexpression of one PKC isozyme can alter the levels of other PKC isoforms (56). By contrast, using a combination of confocal microscopy, various inhibitors, and biochemical evidence of PKC translocation in RAW 264.7 cells, Larsen et al. (50) found that PKC α was needed for FcγR-stimulated respiratory burst but that only PKC δ and ε were necessary for FcγR-mediated phagocytosis itself. PKC βII and its anchoring protein RACK1 have been found to be up-regulated in rat AMs upon maturation of functional responses such as tumor necrosis factor-α or hydrogen peroxide production and lysozyme release (57). Significant, however, none of these previous studies have confirmed a role for PKC βII in Mø phagocytosis of other particles.
interaction. We cannot at present exclude the possibility that only those AMs that express high amounts of surface PS-R' participate in phagocytosis. However, the fact that only roughly 40% of PMs showed significant staining, yet virtually all PMs ingest apoptotic cells in an annexin V-inhibitable fashion (10), urges caution in interpretation of flow cytometry data using mAb 217. The high background staining seen using this IgM mAb precludes accurate definition of the lower limit of expression, and even small amounts of PS-R' may be sufficient. In addition to the stereo-specific PS-R', PS can be bound by multiple receptors including class B scavenger receptors, CD14, macroapsin (CD68), and thrombospondin-dependent vitronectin receptors (1, 71–73).

The demonstration that resident murine AMs express lesser amounts of multiple PKC isoforms, compared with resident MIE at another body surface, further highlights the distinctive differentiation of this cell type (74, 75). AMs have a mostly suppressive role on the induction of adaptive immune responses within the lung itself (76, 77), permitting local expression of T cell effector functions while inhibiting their proliferative role. AMs have not shown previously to be required for phagocytosis of other particle types.

Regarding the question of the role of PKC in phagocytosis of apoptotic cells, we have seen in other systems (78) that PKC is the only isoform which mediates phagocytosis of apoptotic lymphocytes.2 PKC activity does not correlate with their greatly reduced phagocytosis (but not PS-R) by AMs, which we have recently found also have relatively depressed phagocytosis of apoptotic lymphocytes.3

In summary, these data demonstrate for the first time that MIE phagocytosis of apoptotic cells requires PKC βII, an isoform not shown previously to be required for phagocytosis of other types of particles. This unique PKC isoform requirement may be an important clue to the signaling pathways that mediate suppression of MIE production of proinflammatory mediators on ingestion of apoptotic cells (64, 65). Activation of PKC βII by PS-R' provides a partial explanation for the essential role of this receptor in apoptotic cell ingestion.

Acknowledgments—We thank Dr. Lilli Petruzzelli and all of the members of the Ann Arbor Veterans Affairs Medical Center Research Enhancement Award Program for helpful suggestions, Dr. Valerie Fadok for the generous gift of mAb 217, and Joyce O'Brien for secretarial support.

REFERENCES

10. verification
PKC βII in Phagocytosis of Apoptotic Cells
